Nike's stock sees a 24% dip amid tariff challenges and weak Q4 metrics. Click here to read an analysis of NKE stock now.

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Affirm Holdings is a top investment pick with 2,335% profit growth by 2026, driven by BNPL market expansion and improving ...

Microchip Technology's 2024 struggles with high inventory, debt, and economic challenges make it a risky investment. Read why ...